GenomePlex is a Whole Genome Amplification (WGA) method that allows the researcher to generate a representative, ~500-fold amplification of genomic DNA. The amplification yield is dependent on the purity and amount of starting material. The kit utilizes a proprietary amplification technology based upon random fragmentation of genomic DNA and conversion of the resulting small fragments to PCR-amplifiable OmniPlex® Library molecules flanked by universal priming sites. The OmniPlex® library is then PCR amplified using universal oligonucleotide primers and a limited number of cycles.
All components should be stored at -20 °C. When thawed for use, components should be kept on ice. Stability of the Library Preparation Enzyme will be affected if stored warmer than -20 °C or allowed to remain for long periods at temperatures over 4 °C.
The WGA process is divided into fragmentation, OmniPlex® library generation, and PCR amplification. The first two steps, fragmentation and library generation, should be carried out sequentially, as the ends of the library DNA can degrade thus affecting subsequent steps. OmniPlex® library DNA, generated in the stepped isothermal reactions, can be stored up to three days at -20 °C without detectable differences in the process. The final WGA DNA should be stored at -20 °C, and is as stable as any comparably stored genomic DNA sample.
The starting amount of DNA is critical. When using a complex starting material, such as human genomic DNA, the gene bias in the resulting GenomePlex product is significantly altered if the quantity of input DNA is reduced. One ng of human genomic DNA affords product with gene representation that varies 2-10-fold from the original material, while product yield is only ~50% lower. Less complex genomes, such as bacterial DNA, can provide representation with as few as 1 ng of input DNA.
GenomePlex can be used on archival fixed tissue DNA or degraded samples provided that the extracted DNA is 200 bp or greater in size. However, greater quantities of damaged DNA are required to afford acceptable yields of final product. We recommend using up to 100 ng of fixed tissue DNA, and following the complete protocol, including fragmentation.
Experiments should be performed with a positive control DNA sample, such as the Control Human Genomic DNA included in the kit.
After cycling is complete, maintain the reactions at 4° C or store at -20° C until ready for analysis or purification. The stability of WGA DNA is equivalent to genomic DNA stored under the same conditions.
Purification of the final product is recommended before being used in subsequent applications. GenomePlex WGA amplified DNA may be purified with PCR Cleanup Kit (Product No. NA1020) or standard purification methods that isolate single and double stranded DNAs. Once purified, the DNA can be quantified by measuring absorbance, assuming that one A260 unit is equivalent to 50 ng/µL DNA. Measurement techniques such as PicoGreen® dye will often underestimate the actual WGA DNA yield, since single stranded DNA might be generated during amplification.
A 10 ng sample of standard human genomic DNA must yield 3-7 µg of product. The quality and representation of amplification is determined by real-time PCR using primer sets for eight separate loci.
1. How does GenomePlex work?
Genomic DNA is randomly fragmented and the resulting product is manipulated to attach a common sequence at each DNA end. This library of fragments is amplified using fourteen rounds of PCR.
2. What if fragmentation is allowed to proceed for less or more than four minutes?
The 4 minute fragmentation time was found to give optimal results over a wide variety of DNA samples. Too little or no fragmentation will afford low yields and poor gene representation in the resulting WGA product. A ten minute fragmentation step will also give poor WGA yields in almost all cases because a significant fraction of the DNA has is now too small to allow efficient library production.
3. What is the average size of fragmented DNA?
The mean size after the fragmentation step is ~0.4kb.
4. Can GenomePlex be used on archival fixed tissue DNA or degraded samples?
Yes, provided that the extracted DNA is 200 bp or greater in size. However, more damaged DNA is required to afford acceptable yields of final product. We recommend using up to 10 ng of fixed tissue DNA and following the complete protocol, including fragmentation. See the troubleshooting guide under low yield, input DNA is degraded.
5. Can I use less input DNA in the GenomePlex protocol?
When using a complex starting material, such as human genomic DNA, the gene bias in the resulting GenomePlex output is significantly altered if the input DNA is reduced. An input of 1 ng of human genomic DNA affords product with gene representation that varies 2-10‑fold over the original material, even though the yield is only ~50% lower. However, less complex genomes such as bacterial DNA can give good representation with only 1 ng of input DNA.
6. How should WGA DNA be purified? Is there a preferred way to quantify GenomePlex DNA?
We recommend purifying GenomePlex DNA using our PCR cleanup kit (Product No. NA1020) before it is used in any downstream process. Once purified, the DNA can be quantified by measuring absorbance, assuming that one A260 unit is equivalent to 50 ng/mL DNA. Measurement techniques such as PicoGreen® will often underestimate the actual WGA DNA yield, since single stranded DNA might be generated during amplification.
7. How can I store GenomePlex DNA? Where can I stop during the GenomePlex process?
The WGA process can be divided into fragmentation, generation of the OmniPlex® library, and PCR amplification. Fragmented DNA should be processed immediately because the ends of this DNA can degrade and will affect subsequent steps. OmniPlex® library DNA, generated in the stepped isothermal reactions, can be stored up to three days at -20 °C without detectable differences to the process. Store the final WGA DNA at -20 °C; it is as stable as any comparably stored genomic DNA sample
8. Will the GenomePlex process afford product with a negative control (no input DNA)?
No-template controls will occasionally afford product. This no-template product will not contain genes of interest if probed using PCR or hybridization techniques.
9. What studies were conducted to determine sequence fidelity for this whole genome amplification method?
The GenomePlex method was tested for representation during development of the product by using 107 different human primer sets along with PCR and quantitative PCR. The sets are all from the National Center for Biotechnology UniSTS database.* While this subset of 107 DNA sequences represents a small fraction of the 20-30,000 human genes, it is an adequate statistical representation of the human genome.
Collaborators have also published work showing the representation of the amplification obtained using GenomePlex.1,2
As part of our QC protocol, every lot of our whole genome amplification (WGA) kit is run on human genomic DNA, which is subsequently tested using QPCR and eight different UniSTS primer sets. The results are compared to an equal amount of unamplifed DNA. This test demonstrates equal representation over several different regions.
Our GenomePlex WGA Kit is for R&D use only, not for drug, household or other uses. Consult the MSDS for information regarding hazards and safe handling practices.
GenomePlex and OmniPlex® are Registered Trademarks of Rubicon Genomics. This product is for research use only. Use of this product for human or animal therapeutic or diagnostic purposes requires licensing from Rubicon Genomics, Inc. Unauthorized use violates proprietary rights of Rubicon Genomics, Inc.